306 related articles for article (PubMed ID: 33054120)
1. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Cherniawsky HM; Kukreti V; Reece D; Masih-Khan E; McCurdy A; Jimenez-Zepeda VH; Sebag M; Song K; White D; Stakiw J; LeBlanc R; Reiman A; Aslam M; Louzada M; Kotb R; Gul E; Atenafu E; Venner CP
Haematologica; 2021 Jun; 106(6):1733-1736. PubMed ID: 33054120
[No Abstract] [Full Text] [Related]
2. Lenalidomide maintenance in Myeloma - a goldilocks problem?
Ng Liet Hing M; Khot A
Leuk Lymphoma; 2023 Oct; 64(10):1611-1614. PubMed ID: 37671741
[No Abstract] [Full Text] [Related]
3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.
Mancuso K; Tacchetti P; Pantani L; Rocchi S; Rizzello I; Caratozzolo I; De Cicco G; Fusco A; Testoni N; Terragna C; Marzocchi G; Martello M; Borsi E; Dozza L; Cavo M; Zamagni E
Bone Marrow Transplant; 2020 Sep; 55(9):1865-1867. PubMed ID: 32103147
[No Abstract] [Full Text] [Related]
8. Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
Mian H; LeBlanc R; Louzada M; Masih-Khan E; McCurdy A; Venner CP; Stakiw J; Kardjadj M; Jimenez-Zepeda VH; Sebag M; White D; Aslam M; Song K; Reiman A; Kotb R; Gul E; Reece D
Cancer Med; 2023 Feb; 12(4):4357-4362. PubMed ID: 36161712
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
10. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
11. Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G; Di Renzo N; Cascavilla N; Carella AM; Guarini A; Mazza P; Melillo L; Pavone V; Tarantini G; Curci P; Falcone AP; Germano C; Mele A; Merchionne F; Palazzo G; Palumbo G; Quinto AM; Reddiconto G; Rossini B; Spina A; Sgherza N; Specchia G; Musto P; Pastore D
Leuk Lymphoma; 2023 Oct; 64(10):1715-1718. PubMed ID: 37417467
[No Abstract] [Full Text] [Related]
12. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
13. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
[TBL] [Abstract][Full Text] [Related]
14. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A; Manz K; Pfirrmann M; Hänel M; Schwarzer AC; Prange-Krex G; Fabisch C; Knop S; Illmer T; Krammer-Steiner B; Hochhaus A; von Lilienfeld-Toal M; Mügge LO
J Cancer Res Clin Oncol; 2020 Mar; 146(3):749-759. PubMed ID: 31788741
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
[TBL] [Abstract][Full Text] [Related]
18. Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis".
Davies FE; Saunders E; Bourhis F; Guyot P
Ann Hematol; 2022 Jul; 101(7):1599-1601. PubMed ID: 35179641
[No Abstract] [Full Text] [Related]
19. A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study.
Hassoun H; Bayer R; Devlin S; Gentile T; Becker M; O'Dweyer K; Lesser M; Landau H; Chung D; Giralt S
Leuk Lymphoma; 2020 Feb; 61(2):488-490. PubMed ID: 31957517
[No Abstract] [Full Text] [Related]
20. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
